Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 15,000 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 15,000 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $26.22, for a total value of $393,300.00. Following the transaction, the chief marketing officer directly owned 15,000 shares in the company, valued at approximately $393,300. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, April 1st, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $29.46, for a total value of $441,900.00.
• On Friday, March 20th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $49.10, for a total value of $736,500.00.
• On Tuesday, March 10th, Harold Bernstein sold 30,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $50.45, for a total value of $1,513,500.00.

Maze Therapeutics Trading Down 4.1%

Shares of NASDAQ:MAZE opened at $24.50 on Tuesday. The company has a market cap of $1.36 billion, a P/E ratio of -9.68 and a beta of 2.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. Maze Therapeutics, Inc. has a 1 year low of $9.15 and a 1 year high of $53.65. The stock’s fifty day moving average price is $33.00 and its 200-day moving average price is $37.92.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million during the quarter. Sell-side analysts expect that Maze Therapeutics, Inc. will post -2.63 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on MAZE. HC Wainwright increased their target price on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. JPMorgan Chase & Co. increased their target price on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. Truist Financial lowered their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 14th. Finally, Mizuho raised Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $66.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC increased its position in Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. increased its position in Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after buying an additional 915,342 shares in the last quarter. Marshall Wace LLP increased its position in Maze Therapeutics by 3,868.5% in the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after buying an additional 758,104 shares in the last quarter. Caligan Partners LP purchased a new stake in Maze Therapeutics in the fourth quarter worth about $22,794,000. Finally, ArrowMark Colorado Holdings LLC purchased a new stake in Maze Therapeutics in the third quarter worth about $14,135,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.